https://scholars.lib.ntu.edu.tw/handle/123456789/517581
標題: | Taiwanese Dermatological Association consensus statement on management of psoriasis | 作者: | TSEN-FANG TSAI Lee C.-H. Huang Y.-H. Chi C.-C. Chang Y.-T. Wong T.-W. Yang C.-H. Wang L.-F. |
公開日期: | 2017 | 出版社: | Elsevier Ltd | 卷: | 35 | 期: | 2 | 起(迄)頁: | 66-77 | 來源出版物: | Dermatologica Sinica | 摘要: | Background Effective management of psoriasis is a cause for much concern. In Taiwan, there is a lack of consensus on management strategies for psoriasis, especially the principles of drug prescribing in psoriatic patients. Objectives The Taiwanese Dermatological Association convened Expert Panel meetings three times between 2012 and 2015 to discuss the management strategies for treatment of psoriasis in order to fill the knowledge gap and provide a reference tool for Taiwanese dermatologists. Results This paper reports the final output from the three meetings, with the aim of aiding clinical decision making in terms of principles of prescribing, including dosing strategies, efficacy profiles, and safety concerns in connection with eight categories of antipsoriatic treatment: topical agents, phototherapy, nonbiologic conventional systemic agents, licensed biologic systemic agents, newly emerging therapies, combination therapy, transitional therapy, and traditional Chinese medicine. Conclusion The Expert Panel, comprising distinguished Taiwanese dermatologists, succeeded in developing a consensus about the management of psoriasis in Taiwanese patients. Unavailability of data in certain areas may suggest a possibility of new directions in research. ? 2017 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015297421&doi=10.1016%2fj.dsi.2017.01.002&partnerID=40&md5=b59c95512f1da09a1583c49b142b36dd https://scholars.lib.ntu.edu.tw/handle/123456789/517581 |
ISSN: | 1027-8117 | DOI: | 10.1016/j.dsi.2017.01.002 | SDG/關鍵字: | adalimumab; antipsoriasis agent; apremilast; biological product; cyclosporin; etanercept; etretin; infliximab; methotrexate; tofacitinib; topical agent; ustekinumab; Article; Chinese medicine; clinical decision making; consensus development; dermatologist; disease severity; drug efficacy; drug safety; human; hyperkeratosis; medical society; medication therapy management; nail psoriasis; onycholysis; phototherapy; prescription; psoriasis; Psoriasis Area and Severity Index; PUVA; systemic therapy; Taiwanese; topical treatment |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。